The COVID-19 pandemic has demonstrated that it is essential for biopharmaceutical organizations to act quickly and become flexible in production. Experts, such as the CHEManager International team, view four factors as unsolved challenges. They claim that the first challenge is COVID-19 related.
With COVID-19 vaccines becoming more widely available around the world, and countries everywhere easing restrictions, a return to normal is now on everyone’s mind. While many activities are still recovering and regulations remain an important part of our daily lives, optimism is now rising for the
